[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"chemotherapy-induced-cardiotoxicity\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:chemotherapy-induced-cardiotoxicity":40},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":4,"hasResults":10,"nctId":11,"briefTitle":12,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":10,"sex":15,"minAge":16,"maxAge":17,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":29,"lastUpdatePostDateStruct":30,"startDateStruct":33,"completionDateStruct":35,"leadSponsor":37,"locationsCount":4},"100625213",false,"NCT07419711","Grape Polyphenols for Prevention of Chemotherapy-Induced Cardiotoxicity","Cardioprotective Effects of Grape Polyphenols to Reduce Chemotherapy-Induced Cardiotoxicity in Breast Cancer Patients: A Randomized Pilot Study","Inclusion Criteria:\n\n* Female patients aged 30 to 75 years.\n* Histologically confirmed breast cancer.\n* Planned treatment with anthracycline- and\u002For trastuzumab-based chemotherapy.\n* High or very high risk of chemotherapy-induced cardiotoxicity (≥20%), based on clinical assessment.\n* Eastern Cooperative Oncology Group (ECOG) performance status 0-3.\n* Ability to take oral study products.\n* Willingness to comply with study procedures and follow-up visits.\n* Written informed consent provided prior to any study procedures.\n\nExclusion Criteria:\n\n* ECOG performance status of 4.\n* Pre-existing severe cardiovascular disease that would interfere with study participation.\n* Permanent atrial fibrillation or other clinically significant arrhythmias.\n* Severe hepatic or renal impairment.\n* Active central nervous system tumors or metastases.\n* Uncontrolled arterial hypertension.\n* Acute gastrointestinal diseases that may impair absorption.\n* Known allergy or intolerance to grape products or study components.\n* Participation in another interventional clinical trial that may interfere with the outcomes of this study.","FEMALE","30 Years","75 Years",{"count":19,"type":20},120,"ESTIMATED","INTERVENTIONAL",[23],"NA","This pilot randomized clinical study aims to evaluate the cardioprotective effects of a grape polyphenol concentrate in patients receiving anthracycline- and\u002For trastuzumab-based chemotherapy. Adult patients at high or very high risk of chemotherapy-induced cardiotoxicity will be randomized to receive either a grape polyphenol concentrate or placebo for three months, starting with chemotherapy. Cardiac function and cardiotoxicity will be assessed using echocardiographic parameters and circulating biomarkers at baseline, 3 months, and 6 months.",[26,27],"Chemotherapy-induced Cardiotoxicity","Breast Cancer","NOT_YET_RECRUITING","2026-02-16",{"date":31,"type":32},"2026-02-19","ACTUAL",{"date":34,"type":20},"2026-02-09",{"date":36,"type":20},"2027-11-01",{"name":38,"class":39},"Nazarbayev University","OTHER",""]